Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing PI3K/Akt pathway

Cancer Letters

Volumn 286, Issue 2, 2009, Pages 232-239

  Zhang, Feng ^a   Zhang, Tao ^b   Jiang, Tao ^b   Zhang, Rong ^a   Teng, Zeng hui ^a   Li, Chen ^a   Gu, Zhong Ping ^b   Mei, Qibing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

A549 cells; Apoptosis; PI3K Akt; Roscovitine; Wortmannin

Indexed keywords

CASPASE 3; CYTOCHROME C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; ROSCOVITINE; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OLIGOMERIZATION; PRIORITY JOURNAL; SOLID TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLOW CYTOMETRY; HCT116 CELLS; HELA CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; QUINOLINES; SIGNAL TRANSDUCTION;

EID: 71549119169     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.05.039     Document Type: Article

References (34)

1. Meijer L., Borgne A., Mulner O., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 (1997) 527-536
2. Tirado O.M., Mateo-Lozano S., and Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res. 54 (2005) 9320-9327
3. Mohapatra S., Chu B., Zhao X.H., et al. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 65 (2005) 7717-7723
4. Lacrima K., Valentini A., Lambertini C., et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann. Oncol. 16 (2005) 1169-1176
5. Mohapatra S., Chu B., Wei S., et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 63 (2003) 8523-8530
6. Zhang F., Zhang T., Gu Z.P., et al. Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J. Radiat. Res. 49 (2008) 541-548
7. Zhivotovsky B., and Orrenius S. Defects in the apoptotic machinery of cancer cells: role in drug resistance. Semin. Cancer Biol. 13 (2003) 125-134
8. Itoh N., Semba S., Ito M., et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94 (2002) 3127-3134
9. Mungamuri S.K., Yang X., Thor A.D., et al. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 66 (2006) 4715-4724
10. Corvera S., and Czech M.P. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol. 8 (1998) 442-446
11. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
12. Havasi A., Li Z.J., Wang Z.Y., et al. Hsp27 inhibits Bax activation and apoptosis via a PI3 kinase-dependent mechanism. J. Biol. Chem. 283 (2008) 12305-12313
13. Cardone M.H., Roy N., and Stennicke H.R. Et al., Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
14. Liu Z., and Roberts T.M. Human tumor mutants in the p110α subunit of PI3K. Cell Cycle 5 (2006) 675-677
15. Huang C., Mandelker D., Gabelli S.B., et al. Insights into the oncogenic effects of PIk3CA mutations from the structure of p110α/p85α. Cell Cycle 7 (2008) 1151-1156
16. Kang S., Bader A.G., Zhao L., et al. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4 (2005) 578-581
17. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 (2006) 77-82
18. Ng S.S.W., Tsao M.S., Chow S., et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60 (2000) 5451-5455
19. Yu C., Rahmani M., Dai Y., et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells procede through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. 63 (2003) 1822-1833
20. Cory A.H., Somerville L., and Cory J.G. Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine, wortmannin and UCN-01. Anticancer Res. 25 (2005) 101-106
21. Powis G., Bonjouklian R., Berggren M.M., et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 54 (1994) 2419-2423
22. Okada T., Sakuma L., Fukui Y., et al. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J. Biol. Chem. 269 (1994) 3563-3567
23. Kroemer G. Mitochondrial implication in apoptosis: towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ. 4 (1997) 443-456
24. Reed J.C. Cytochrome c: can't live with it-can't live without it. Cell 91 (1999) 559-562
25. Susin S.A., Zamzami N., Castedo M., et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184 (1996) 1331-1341
26. Antignani A., and Youle R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?. Curr. Opin. Cell Biol. 18 (2006) 685-689
27. Engelman J.A., Luo J., and Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7 (2006) 606-619
28. Okudela K., Hayashi H., Ito T., et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation. Am. J. Pathol. 164 (2004) 91-100
29. Wesierska-Gadek J., Gueorguieva M., and Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol. Cancer Ther. 4 (2005) 113-124
30. Xiao D., and Singh S.V. Diallyl trisulfide, a constituent of processed garlic, inactivates Akt to trigger mitochondrial translocation of BAD and caspase-mediated apoptosis in human prostate cancer cells. Carcinogenesis 27 (2006) 533-540
31. Gardai S.J., Hildeman D.A., Frankel S.K., et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 279 (2004) 21085-21095
32. Kim H.J., Oh J.E., Kim S.W., et al. Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cells. Cancer Lett. 206 (2008) 88-95
33. Ling Y.H., Lin R., and Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol. Pharmacol. 74 (2008) 793-806
34. De Giorgi F., Lartigue L., Bauer M.K., et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J. 16 (2002) 607-609